Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med Starts First US Trial of Fruquintinib, an Anti-Angiogenesis Drug

publication date: Dec 15, 2017

Hutchison China MediTech (Chi-Med) announced the start of a US Phase I bridging trial of its lead drug, fruquintinib, in patients with solid tumor cancers. Fruquintinib is a VEGFR inhibitor with an anti-angiogenesis mechanism. In China, Chi-Med has completed all three clinical trial phases of fruquintinib and filed for market approval in colorectal cancer patients. In 2013, Lilly partnered China rights to fruquintinib with Chi-Med in an $86 million deal, though so far, it has not extended that agreement to the rest of the world. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.